Introduction
Asthma, a chronic disorder characterized by impaired respiratory function and/or airflow, is one of the most common disorders worldwide and the leading chronic disease in children. Currently, an estimated 14 million individuals, including ∼ 11 million children, in the USA have been diagnosed with asthma in their lifetime, with prevalence increasing by ∼ 1-2% each year [1] .
Several genes have been validated as risk factors for asthma susceptibility and receptiveness controller therapies [2] , including ADRB2, a 2015-bp-long intronless gene found on chromosome 5q31-32. ADRB2 encodes the β-2-adrenergic receptor (β2-AR), a type of G-proteincoupled receptor that is highly expressed in bronchial smooth muscle cells. Risk-associated/outcome-associated single nucleotide polymorphisms (SNPs) identified in the coding region of the ADRB2 gene include Arg16Gly (rs1042713) and Gln27Glu (rs1042714), both of which occur in amino acids found near the protein's ligand binding site for epinephrine [2] . In-vivo studies of ADRB2 SNPs at rs1042713 and rs1042714 suggest that, in general, these variants are most likely not disease-causing but instead potentially indicate/predict responsiveness to agonists and antagonists [3] .
In seeking to further delineate the impact of ADRB2 variants on asthma outcome, we control for severity, guideline adherence, and BMI (long-associated with impaired outcome in terms of severity and susceptibility) [4, 5] . The outcome is measured by asthma exacerbation frequency, adapting an approach by Basu et al. [6] . Many treatment guidelines, including the National Heart, Lung and Blood Institute (NHLBI), specifically focus on reducing exacerbations as a treatment goal and measure Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.pharmacogeneticsandgenomics.com. of treatment efficacy [7] , and a key component of reducing risk in the long term [8] . We hypothesize that, controlling for other factors, patients with Arg16Gly and Gln27Glu polymorphisms experience differential outcome as measured by asthma exacerbation.
Participants and methods
This study was undertaken with the Electronic Medical Records and Genomics consortium. Patients were identified using a phenotyping algorithm that classified cases and severity based on ICD-9 codes, asthma controller therapy, structured queries, and natural language processing. This algorithm had a 96.1% success rate in correctly identifying cases and was validated in pediatric cohorts [9] . Inclusion and exclusion criteria are reviewed briefly (see studies by Almoguera et al. [9] and Hysinger et al. [10] for further details).
Recruitment
Participants were recruited at the Center for Applied Genomics at The Children's Hospital of Philadelphia under a large-scale biobanking/recruitment project 'A Study of the Genetic Causes of Complex Pediatric Disorders' (n > 100 000). After being seen in either the ambulatory or inpatient setting, patients were invited to enroll in the Center for Applied Genomics's project. Our broad consent protocol includes DNA extraction, blood/ sera, electronic health record (EHR) access, and permission to perform genomic studies.
Electronic health record extraction
The EHR product, EpicCare (Epic Systems, Verona, Wisconsin, USA), includes the reason for visit, diagnosis codes (ICD), growth measurements, medications, referrals, all laboratory results, radiology reports, surgical notes, discharge summaries, emergency department summaries, and specialist reports.
Genotyping
SNPs were directly genotyped on a variety of Illumina arrays (primarily HapMap and OMNI) (Illumina Inc., San Diego, California, USA). Ancestry was determined by principal component analysis using Eigenstrat 3.0 (Reich Lab at Harvard University, Cambridge, Massachusetts, USA) on the genotyping data [11, 12] . Samples were separated into African Americans (AAs) and European Americans (EAs) on the basis of principal components, and participants of mixed ancestry were excluded. For the rs1042713 SNP, participants were coded as '0,' '1,' or '2' indicating whether they respectively had zero, one, or two copies of the A allele. Similarly, for rs1042714, patients were coded as '0,' '1,' or '2' for the G allele (Table 1) .
Inclusion/exclusion criteria
Asthma cases were defined as children older than 4 and younger than 18 years of age who received an ICD-9 asthma code (493.*) on at least two separate calendar days as well as documented prescription(s) for at least one asthma-related medication. Only asthmatics evaluated in allergy or pulmonology clinics were included.
Children were excluded if they had evidence of chronic lung disease defined by ICD-9 codes 238.77, 273. 4 
Guideline adherence
We defined 'meeting the NHLBI guidelines' as having all five of the following requirements: (i) documented asthma control test, (ii) asthma care plan in the EHR (iii) bi-annual follow-up visits (determined using a threshold of 75% of visits being within 200 days of one another), (iv) pulmonary function test (PFT) data, and (v) on at least one inhaled corticosteroids (ICS) medication [8] . Prescriptions for asthma-related medications (i.e. leukotriene agonists, ICS/LABA) in addition to ICS were noted and considered beyond the scope of the guidelines. Medication adherence was recorded but patient data was limited (available in <40% patients) and therefore not included. Patients whose treatment met all criteria were coded as '1' versus '0' where at least one criterion was missed.
Outcomes measures
Only visits considered 'asthma-related,' defined as having a diagnosis of asthma on the same day, were considered. Exacerbations were defined as a prescription for systemic steroids with an associated asthma (ICD-9 493.*) diagnosis on the same calendar day. Steroid prescriptions within 14 days of a previous prescription were considered the same exacerbation. Any exacerbation within the 1 January 2008 and 1 June 2016 timeframe was included.
Analysis plan
Given an eligible cohort of 4661 patients that met algorithm criteria, we randomly selected 400 cases, in whom direct genotyping data was available (the remainder of whom will be directly genotyped/analyzed as part of phase 2 studies). Analyses were performed in two stages, comparing the Role of ADRB2 SNPs Sood et al. 257
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effects of genotype on outcome in (i) AAs and EAs separately, and (ii) AA and EA cohorts combined. Exacerbations were coded as present/absent contingent on whether the patient did/not experience an exacerbation in the previous 12 months. This approach is similar to Basu et al. [6] who used exacerbations/last 6 months as the primary outcome measure. Individuals with a z-score-adjusted BMI greater than 95% were excluded from analyses.
Results

Guideline adherence
Of 400 cases studied, 379 had an updated asthma care plan, 224 had at least one completed asthma control test, 368 had PFT data, all 400 had a prescription for at least one ICS medication, and 243 had bi-annual follow-up visits. For the most part, total guideline adherence was evenly distributed. Adherence to all the guidelines seemed to increase with more recent birth years, possibly because older patients had experienced contact with the hospitals before the release of the guidelines (Table 2) .
Exacerbation frequency
With severity, compliance, and both genotypes as predictors in a binary logistic regression, we tested the hypothesis that the Arg16Gly and Glu27Gln genotypes were associated with exacerbations. No significant effect of genotype was observed for either ancestral group.
However, in a combined meta-analysis, individuals homozygous for Gln27 were found to be disproportionately more likely to experience exacerbations versus those who were heterozygous (χ 2 = 6.45, P = 0.040) or Glu27 homozygous (χ 2 = 6.16, P = 0.013). We did not correct for multiple comparisons, noting that the direction-of-effect is the same for both comparisons. We did not observe a significant difference between patients who were heterozygous versus Glu27 homozygous (χ 2 = 0.738, P = 0.390). We did not identify any significant differences for rs1042713 (Arg/ Gly16).
Unsurprisingly, there was also a marked effect of severity (χ 2 = 10.02, P = 0.007), with increased severity significantly and increasingly associated with a higher likelihood of experiencing an exacerbation. We also observed a marked effect on patient compliance, which was associated with reduced exacerbation frequency (χ 2 = 32.30, P < 0.001) ( Table 3) .
Discussion
Both Arg16Gly and Gln27Glu have previously been linked to asthma outcome, including response to first-line bronchodilator therapy [2] . Although we found no effect for the Arg16Gly allele, we did uncover an association with Gln27, where individuals were disproportionately more likely to experience an exacerbation versus those who were heterozygous (P = 0.040) or Glu27 homozygous (P = 0.013).
Given β-2-AR's known role in bronchodilation, medications that influence bronchodilation may interact differently with the protein depending on the SNP. Mutations at or near the active site could impact the efficacy of the β-agonist medication. As ICS medications work to reduce the inflammation that can affect bronchodilation, these mutations could also impact the efficacy of ICS. Already, several studies have shown that varying the use of β-agonists treatments like albuterol with polymorphic patients has brought about poorer results in airway function improvement, with patients with polymorphisms at codons 16 or 27 largely seeing no improvement in peak flow as compared with patients without these SNPs [13] . Furthermore, a study in COPD patients found that patients treated with ICS did not respond as well to longacting β-agonist treatment − patients with rs1042713 had exacerbations sooner with ICS compared with without Birth year  2002-2008  170  165  101  149  170  124  71  1996-2001  153  146  85  143  153  79  46  1989-1995  50  44  11  46  50  22  6  Sex   a   Female  141  136  79  129  141  72  42  Male  230  217  116  207  230  152  80  Ancestry  African American  166  165  127  157  166  100  80  European American  207  190  70  181  207  125  43  BMI percentile (%)  0-25  45  42  18  37  45  28  12  25-50  62  56  27  56  62  43  16  50-75  87  83  50  81  87  58  36  75-100  179  174  102  164  179  96  59  Atopy  Yes  354  336  186  321  354  211  114  No  19  19  11  17  19  14  9  Total  373  355  197  338  373  225  123 ICS medication was adhered to by all included participants (n = 373), as this was an inclusionary criterion. This was followed by asthma care plan (355), pulmonary function testing (338), regular visits (225), and asthma control tests (197 Overall effect of the Gln/Glu27 genotype on asthma exacerbations at a mean frequency of every 6 months or more. There was no difference for individuals of African American or European American Ancestry when analyzed separately, but the difference did reach significance when meta-analyzed.
ICS [14] . Acknowledging the caveat of a limited sample size − and by association relatively modest power − these support the suggestion that ADRB2 SNPs affect the efficacy and interaction of common asthma medications. These findings underscore the potential relevance of incorporating patients' genotypic information into their asthma treatment plans, where medical teams can leverage genotype information to develop individualized treatment plans.
That our results do not show an association between the Arg16Gly SNP and asthma exacerbations is surprising given that many studies have supported an association between the two and the Arg16Gly allele is in linkage with Gln27 [15] . However, the effect of these SNPs on asthma outcome has been seen to greatly vary by race, with many Asian populations exhibiting an association between Arg16Gly and asthma susceptibility [16] [17] [18] [19] . In comparison, Gln27 has not been the focus of many studies.
In parallel, this study also illustrates how EHR data linked to genotypes can systematically be used to delineate health outcomes for disease populations. By showing associations between genotype and response to inhaled corticosteroid treatment as reflected in the frequency of asthma exacerbations for asthma, we outline a model whereby systematic data mining of biobanked samples, which are coupled to EHRs can be used to identify genotype-health outcome associations and inform treatment (for appropriately consented participants). This demonstrates a success for data mining of de-identified EHR data, and the utility of unbiased largescale recruitment and biobanking in informing pharmacogenomic effects for common diseases.
